Loading stock data…
$3.47-0.35 (-9.16%)
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Opus Genetics, Inc. in the Healthcare sector is trading at $3.47 with a market capitalization of $301M. Wall Street consensus targets $13.47 (17 analysts), implying a +288.2% move over the next 12 months. The stock is currently 51% below its 52-week high of $7.07, remaining 16.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $755,000↓ | $2.16M↓ | $3.87M↑ | $3.08M↑ | $2.88M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.48M↓ | -$14.36M↓ | -$11.45M↓ | -$8.31M↑ | -$8.91M |
| Net Income | -$8.10M↑ | -$65.53M↓ | -$16.52M↑ | -$17.45M↓ | -$7.42M |
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It d...